Clinicians can help their patients tap into personal resilience, and such characteristics as grit, gratitude and grace, to manage their chronic pain, says Afton L. Hassett, PsyD.
Search results for: osteoporosis
New Clinical Trials for Ustekinumab & Denosumab Biosimilars Begin Recruitment
Clinical trials of biosimilar treatments, including a phase 1 study of SB17, which is biosimilar to ustekinumab, and two phase 3 studies investigating of SB16, which is biosimilar to denosumab, are currently recruiting.
Tips for Balancing Medication Treatment & Risk in Elderly Patients
ACR CONVERGENCE 2020—With the inevitable decline in organ function that comes with age, and the likelihood that older patients (i.e., generally defined as older than 60 or 70, depending on the study) are on more than one medication due to multiple comorbidities, therapeutic drug treatment for older patients requires persistent vigilance and know-how, two experts…
The Prevention & Management of Medication-Related Osteonecrosis of the Jaw
Medication-related osteonecrosis of the jaw (MRONJ) is a condition that manifests as exposed, necrotic and non-healing jaw bone in patients who have been treated with bisphosphonates, denosumab, chemotherapeutic agents, anti-angiogenic drugs, tyrosine kinase inhibitors, thalidomide and steroids.1-4 These medications are administered via intravenous, subcutaneous and oral routes to manage osteopenia; osteoporosis; hypercalcemia of malignancy; bone…
Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss
NEW YORK (Reuters Health)—Long-term glucocorticoid users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab vs. oral alendronate, a small clinical trial shows. The drug also proved superior at lowering bone-turnover markers at 12 months, researchers in Hong Kong report in Bone.1 “Denosumab may be considered as an alternative first-line…
Rosalind Ramsey-Goldman, MD, DrPH, Becomes Next Chair of the Collaborative Initiatives Special Committee
At the helm of the Collaborative Initiatives Special Committee (COIN), Rosalind Ramsey-Goldman, MD, DrPH, will oversee projects to tackle disparities within rheumatologic care, improve the inclusiveness of ACR initiatives, advance professional development in rheumatology topics and more.
Denosumab Promising for Osteolysis after Total Hip Replacement
NEW YORK (Reuters Health)—Denosumab showed biological efficacy against osteolysis after total hip replacement in a proof-of-concept trial. “Denosumab is already a well-established licensed drug for the indications of osteoporosis and metastatic bone lesions in cancer, and has been shown to be effective in reducing erosions in inflammatory arthritis,” Dr. Mark J.M. Wilkinson of the University…
Tips for Addressing Leg Length Discrepancy in Osteoarthritis
Humans are not perfectly symmetrical. Almost everyone has one ear that’s higher or one foot that’s larger than the other. Similarly, leg lengths are often not quite the same. There is disagreement as to what constitutes a clinically significant difference, but some studies suggest that leg length discrepancy (LLD) can lead to osteoarthritis (OA) of…
ACR Advocacy: 2020 Year in Review
As a new year begins, Government Affairs Committee Chair Blair Solow, MD, takes stock of ACR advocacy wins in 2020 and issues to watch in 2021, including workforce issues, continued telemedicine access, prior authorization relief, Medicare reimbursement and drug pricing.
Therapeutic Exercise for Bone Health
ACR CONVERGENCE 2020—Attention to bone health in people at risk of developing, or who already have, osteoporosis is essential to reduce their increased risk for fragility fractures. Major risk factors for osteoporosis include being female, white, of small frame and having a family history of osteoporosis, as well as having secondary causes of osteoporosis, such…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 59
- Next Page »